Affected by an aggressive form of the disease, Jasmin David turned to a specialized hospital as a last resort.
Although the survival rate for breast cancer can be as high as 90% in some high-income countries, it is still the deadliest cancer in women. And according to figures from the World Health Organization, “nearly one in twelve women will develop breast cancer in her lifetime”.
This is the case of Jasmin David, a 51-year-old Briton, who was diagnosed in November 2017 with an aggressive form of the disease. She discovers a few months later that her cancer has spread “to the lungs, rib cage and lymph nodes”, reports The Independent. His doctors only give him a year to live.
Despite this announcement, Jasmin David, mother of two children, continued her chemotherapy sessions and underwent a mastectomy in April 2018. She was then treated with radiotherapy, which finally rid her of her cancer. But in October 2019, the disease returns.
As a last resort, David decides to join a two-year Phase 1 clinical trial at the National Institute for Health and Care Research (NIHR) Clinical Research Facility (CRF) at The Christie Hospital in Manchester, known as one of the largest cancer treatment centers in Europe.
During the trial, she is asked to take an experimental drug “combined with an immunotherapy drug, atezolizumab, which she must inject every three weeks.” In June 2021, the verdict falls: his scanners no longer show any trace of cancer.
Very good results
“When I was offered the trial, I didn’t know if it would work for me,” she told the Manchester Evening News. “But I thought to myself that at least I could do something to help others and the next generation.” Despite many “effects…
Read more on Slate.fr.
VIDEO – Dr Christian Recchia: “Breast cancer in women is 12,000 deaths per year in France”